194 related articles for article (PubMed ID: 7750599)
1. Relationship between circulating human chorionic gonadotropin levels and premature luteinization in cycles of controlled ovarian hyperstimulation.
Copperman AB; Horowitz GM; Kaplan P; Scott RT; Navot D; Hofmann GE
Fertil Steril; 1995 Jun; 63(6):1267-71. PubMed ID: 7750599
[TBL] [Abstract][Full Text] [Related]
2. Premature luteinization in controlled ovarian hyperstimulation has no adverse effect on oocyte and embryo quality.
Hofmann GE; Bentzien F; Bergh PA; Garrisi GJ; Williams MC; Guzman I; Navot D
Fertil Steril; 1993 Oct; 60(4):675-9. PubMed ID: 8405524
[TBL] [Abstract][Full Text] [Related]
3. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Escudero EL; Boerrigter PJ; Bennink HJ; Epifanio R; Horcajadas JA; Olivennes F; Pellicer A; Simón C
J Clin Endocrinol Metab; 2005 Apr; 90(4):2081-8. PubMed ID: 15483085
[TBL] [Abstract][Full Text] [Related]
4. Premature luteinization: could it be an early manifestation of low ovarian reserve?
Younis JS; Haddad S; Matilsky M; Ben-Ami M
Fertil Steril; 1998 Mar; 69(3):461-5. PubMed ID: 9531877
[TBL] [Abstract][Full Text] [Related]
5. Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist.
Younis JS; Matilsky M; Radin O; Ben-Ami M
Fertil Steril; 2001 Aug; 76(2):294-9. PubMed ID: 11476775
[TBL] [Abstract][Full Text] [Related]
6. Premature luteinization is not eliminated by pituitary desensitization with leuprolide acetate in women undergoing gonadotrophin stimulation who demonstrated premature luteinization in a prior gonadotrophin-only cycle.
Hofmann GE; Bergh PA; Guzman I; Masuku S; Navot D
Hum Reprod; 1993 May; 8(5):695-8. PubMed ID: 8314961
[TBL] [Abstract][Full Text] [Related]
7. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
8. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH.
Ubaldi F; Camus M; Smitz J; Bennink HC; Van Steirteghem A; Devroey P
Fertil Steril; 1996 Aug; 66(2):275-80. PubMed ID: 8690116
[TBL] [Abstract][Full Text] [Related]
9. Premature luteinization defined as progesterone estradiol ratio >1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin-releasing hormone agonist cycles.
Ozçakir HT; Levi R; Tavmergen E; Göker EN
J Obstet Gynaecol Res; 2004 Apr; 30(2):100-4. PubMed ID: 15009611
[TBL] [Abstract][Full Text] [Related]
10. Increased progesterone/estradiol ratio on the day of HCG administration adversely affects success of in vitro fertilization-embryo transfer in patients stimulated with gonadotropin-releasing hormone agonist and recombinant follicle-stimulating hormone.
Ou YC; Lan KC; Chang SY; Kung FT; Huang FJ
Taiwan J Obstet Gynecol; 2008 Jun; 47(2):168-74. PubMed ID: 18603501
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation.
Filicori M; Cognigni GE; Gamberini E; Parmegiani L; Troilo E; Roset B
Fertil Steril; 2005 Aug; 84(2):394-401. PubMed ID: 16084880
[TBL] [Abstract][Full Text] [Related]
12. Elevated luteinizing hormone on the day of human chorionic gonadotropin administration does not reduce cycle fecundity in a low-dose flare-up in vitro fertilization protocol.
Lincoln SR; Long CA; Whitworth NS; Sopelak VM; Cowan BD
Fertil Steril; 1995 Mar; 63(3):563-5. PubMed ID: 7851587
[TBL] [Abstract][Full Text] [Related]
13. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration.
Filicori M; Cognigni GE; Pocognoli P; Tabarelli C; Spettoli D; Taraborrelli S; Ciampaglia W
Hum Reprod; 2002 Aug; 17(8):2009-15. PubMed ID: 12151429
[TBL] [Abstract][Full Text] [Related]
14. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
[TBL] [Abstract][Full Text] [Related]
15. Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation.
Weissman A; Loumaye E; Shoham Z
Hum Reprod; 1996 May; 11(5):943-9. PubMed ID: 8671368
[TBL] [Abstract][Full Text] [Related]
16. Preovulatory luteinization during induction of follicular maturation with menotrophin and menotrophin--clomiphene combination.
Birkenfeld A; Mor-Joseph S; Ezra J; Simon A; Navot D
Hum Reprod; 1990 Jul; 5(5):561-4. PubMed ID: 2118544
[TBL] [Abstract][Full Text] [Related]
17. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
[TBL] [Abstract][Full Text] [Related]
19. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
20. Progesterone rise on the day of HCG administration (premature luteinization) in IVF: an overdue update.
Elnashar AM
J Assist Reprod Genet; 2010 Apr; 27(4):149-55. PubMed ID: 20177771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
